

[View this email in your browser](#)



Randomized Trial to Prevent Vascular Events in HIV



May 2022 Table of Contents

- [Don't Forget to Order Copies of the](#)
- [Site Spotlight: Centro de Referencia e Treinamento DST/AIDS CRS 31954](#)
- [Important Reminders From the Data Management Team](#)
- [FAQs](#)
- [Reporting Potential Adjudicated Events: A Brief Review](#)
- [Lab Tips](#)
- [Next Team/Site Call! July 19th](#)
- [Are You Up to Date?](#)

Don't Forget to Order Copies of the REPRIEVE Participant Newsletter!!!



A message from Dr. Steve Grinspoon and Dr. Pam Douglas, REPRIEVE Co-Principal Investigators

Greetings to you! We hope this newsletter finds you in good health. We recognize it has been a challenging year given the global COVID-19 pandemic, and we are so appreciative of your ongoing participation in REPRIEVE. As contributors to a trial of over 7,000 people living with HIV across 5 continents, we achieved many milestones together this past year. With your help, we have generated key results to improve cardiovascular and overall health among people with HIV. We have come to understand how heart disease risk relates to optimal lifestyle habits and showed factors relating to decreased physical function among our participants. Importantly, we continue to move steadily toward our goal of trial completion, without any major problems or safety issues.

In the upcoming months, you will be asked to sign a revised consent form that extends the trial follow-up, further ensuring that we achieve our goals. Your maximum anticipated length of follow-up will be between 6-10 years, depending on when you enrolled in REPRIEVE. It is important to know that we are not sure if this length of follow-up will be needed. We are setting a maximum length to ensure the necessary trial infrastructure over time, but it is likely the follow-up period will be shorter.

As you may know, the Data and Safety Monitoring Board (DSMB) that oversees REPRIEVE decides when the trial is completed, and their decision is based on the number of heart disease events (things like heart attacks and strokes) that are reported. For this reason, it is important that you report any potential heart events to your study team. Even if you are not sure if you've had a heart event or if you have vague symptoms, please alert your study team as soon as possible so that we capture every single possible heart event. By answering this study's primary research question, we hope to be able to develop heart disease prevention and treatment guidelines tailored specifically for people living with HIV.

REPRIEVE Facts

- > We're celebrating the completion of an additional year of follow-up since the enrollment of the first participants were enrolled in REPRIEVE, with an average participation of about 4 years.
- > REPRIEVE has published almost 20 manuscripts... with more on the way!
- > Findings from REPRIEVE have been presented over 10 times at conferences including the Conference on Retroviruses and Opportunistic Infections, AIDS, Association of Nurses in AIDS Care and the International Association of Clinical Research Nurse conference.

Thank you for your continued participation!

Heart Health Tip!

Mental health and heart health go hand in hand

Mental health is part of overall health. We can't be healthy if we neglect our bodies, and we can't be well if we neglect our mental health. Here are some tips that may positively impact your mental health AND heart health!!!

1. Be active
2. Eat healthy foods
3. Be mindful
4. Avoid smoking and substance abuse



The annual REPRIEVE Participant Newsletter* and translations in 9 languages are now available, [click here!](#)

The newsletter is a great way to keep participants updated about and engaged in REPRIEVE. This year's newsletter includes a message from REPRIEVE leadership, REPRIEVE facts, heart health tips, a message from the Community Advisory Board, a few words from a REPRIEVE participant, and other exciting updates!

If your site has not already requested hard copies please [click here](#) to let us know how many copies you would like and in which languages.

**The newsletter has been approved by the IRB for the CCC, please submit to your local IRB/EC as per your local requirements.*



Site Spotlight: Centro de Referência e Treinamento DST/AIDS CRS 31954



The Casa da Pesquisa site, located in São Paulo, Brazil has been a tremendous contributor to REPRIEVE!

Casa da Pesquisa is the Clinical Trials Unit of the Centro de Referência e Treinamento - DST/AIDS. They have been conducting clinical trials for over 25 years and are an exemplary site for clinical trials in HIV/STI treatment, prevention, and vaccines.

Their site has been participating in REPRIEVE since 2016. A key driver for the team is providing the best care possible to study participants. Enrolled participants receive their clinical care from the study team, which allows for scheduling study visits and clinic visits in tandem.

The team has shared some of their retention tips:

1. Keep in touch with participants - for example, by sending birthday cards and messages.
2. Send reminder messages prior to each scheduled visit, for example, send a reminder visit the day before the scheduled visit.

3. Contact any participants who have not been seen recently through various channels, for example, telephone, text or social media depending on your local IRB/EC approvals.
4. Tailor care during the COVID-19 pandemic to be more flexible, for example, conduct study visits over the phone.

This CRS has very high retention rates (100% of 100 participants are still in follow up) showing that their retention strategies are key for this long-term study.

Thank you, Casa da Pesquisa team, for all your efforts and for sharing your retention tips!



Important Reminders From the Data Management Team

- Remember to **review the AE Log and Medications Log at every visit and update the "Review Date"**, regardless of whether there were updates to make or the data were current.
- The Vital Status and Endpoint Assessment CRF (VSW0025) should be completed for participants who are off-study for reasons other than withdrawal of consent or death.
 - Completion of the form should be yearly, beginning one year from the Off-Study date for the participant based on the RP0001 Off-Study CRF.
 - Section 12.6 of the A5332 MOPS has additional details about Vital Status and Endpoint Assessment
 - If you would like a list of PIDs for whom this CRF may be overdue for completion, contact Evelynne at efulda@mgh.harvard.edu.



FAQs

Q: A participant took a COVID home antigen test in preparation for attending an event, *the test came back positive but he noted no symptoms (asymptomatic)*. This

episode has not been recorded in the participant's medical chart as he made no mention of it to his provider at their last encounter. How do I report this in Openclinica?

A: The team has decided that *participant report* of a positive COVID test (antigen or PCR) is acceptable. When completing the COVID-19 Symptom Assessment CRF (SSW0040), please answer "yes" to Questions 4 and 4a and record the event (asymptomatic COVID-19) on the AE Log. Record the start date as date of test; record end date as 10 days after start date. Do not enter grade on the AE Log, OpenClinica will prompt a grade to be recorded, in place of grade enter message that COVID-19 was asymptomatic. Additional instructions are in section 4.2 of the A5332 MOPS.

Q: A participant took a COVID home antigen test after waking up with a runny nose and slight fever, the test came back positive, the participant did not seek medical attention because the symptoms continued to be mild and resolved after a few days. This episode has not been recorded in the participant's medical chart as she made no mention of it to her provider at their last encounter. How do I report this in Openclinica?

A: The team has decided that *participant report* of a positive COVID test (antigen or PCR) is acceptable. When completing the COVID-19 Symptom Assessment CRF (SSW0040), please answer "yes" to Questions 4 and 4a on the SSW0040 (see snip below) and record the event (COVID-19 diagnosis) on the AE Log. Do not record the related symptoms on the AE log, COVID symptoms are recorded on the SSW0040. Close the COVID-19 diagnosis upon symptom resolution in case the participant develops another episode. Additional instructions are in section 4.2 of the A5332 MOPS.

FAQs in case of collection tube supply shortages!

As you may be aware, the COVID pandemic continues to disrupt supply chains and many labs are experiencing shortages of specimen collection tubes. Therefore, we developed an FAQs document to guide you in case you experience collection tube supply shortages, [click here](#) to download! Please review the FAQs and let the team (actg.corea5332@fstf.org) know if you have any questions.



Reporting Potential Adjudicated Events: A Brief Review


What potential events are we looking for?

- **Cardiovascular endpoints**
 - Atherosclerotic or other CVD death
 - Nonfatal myocardial infarction
 - Unstable angina hospitalization
 - Coronary or peripheral arterial revascularization
 - Peripheral arterial ischemia
- **Cerebrovascular events**
 - Nonfatal stroke or transient ischemic attack (TIA)
- **Death from any cause (see note below)**
- **Additional adjudicated cardiac events not part of the primary endpoint**
 - Heart failure, including all COVID-19-related events resulting in hospitalization

NOTE: All deaths from any cause (CVD or non-CVD related) must be submitted for adjudication by the external events committee (TIMI) who will determine if the event is

CVD-related. The only time a death should be submitted to DAERS as an EAE without first being adjudicated by the CEC is when the death is felt to be study drug-related.

The workflow below outlines the process for submitting potential events in OpenClinica and to the Data Coordinating Center (DCC). Section 6.0 of the REPRIEVE (A5332) MOPS has additional details.





Please be sure to **complete the Specimen Tracking Form in a timely manner and ensure the collection time entered on the Specimen Tracking CRF and in LDMS are identical.** This is important for monitoring the specimen collection status of the trial as well as to prevent lab data queries.

Do you have a lab processing question? We will be having our next site call on July 19th. Please email any questions in advance of this call to the lab team (reprieve.labcom@fstrf.org).

We will also be hosting our annual Shipment/Query refresher call in September 2022! Stay tuned for more details about this call.


Lab Tips



Thank you to everyone who responded to our recent survey about site resources!

Results from the survey showed that site newsletters were identified as the most useful resource, while site newsletters, scorecards, and site calls are utilized most often.

If you have suggestions for additional resources you would like the CCC to develop please don't hesitate to reach out by [email](#)!





Next Team/Site Call! July 19th

1:00 PM US (EDT)
 1:00 PM HAITI (EDT)
 1:00 PM PERU (PET)
 2:00 PM PUERTO RICO (ADT)
 3:00 PM BRAZIL (BRT)
 8:00 PM BOTSWANA (CAT)***
 8:00 PM SOUTH AFRICA (SAST)***
 8:00 PM ZIMBABWE (CAT)***
 9:00 PM UGANDA (EAT)***
 11:30 PM INDIA (IST)***
 1:00 AM 04/20/2021 THAILAND (ICT)***

***We do not expect site staff to join these calls during their off-work hours. Instead we will update you on other scheduled calls, e.g., your calls with the ACTG NCC.

Remember that questions are always welcome at actg.corea5332@fstfrf.org and if there are slides used for a call, they are available on the PSWP in the Protocol Training >> Site Calls folder.

REPRIEVE (A5332): Are You Up to Date?

For A5332 please use:

Protocol Version 5.0 dated 04/01/2019
Version 5.0, Clarification Memo 1 dated 04/03/2020
Version 5.0, Clarification Memo 2 dated 05/04/2020
Version 5.0, Letter of Amendment 1 dated 06/19/2020
Version 5.0, Letter of Amendment 2 dated 12/14/2020
Revised Version! MOPS Version 5.0 dated 04/29/2022
LPC for ACTG Sites Version 5.0 dated 05/04/2020
LPC for Non-ACTG Sites Version 5.0 dated 05/04/2020
 These documents are on the [A5332 PSWP](#)

***For future reference, all newsletters are available on the
REPRIEVE Website***

We welcome ideas and suggestions for future newsletters. Please submit any comments or suggestions to the REPRIEVE News team at reprieve.news@fstfrf.org.



Like, comment, share, and retweet!

REPRIEVE Trial Clinical Coordinating Center

Massachusetts General Hospital
55 Fruit Street, 5LON 207
Boston, MA USA 02114

Want to change how you receive these emails?
You can [update your preferences](#) or [unsubscribe from this list](#).

This email was sent to <<Email Address>>

[why did I get this?](#) [unsubscribe from this list](#) [update subscription preferences](#)
Massachusetts General Hospital · 5 Longfellow Place · Boston, MA 02214 · USA

